#BEGIN_DRUGCARD DB00760

# AHFS_Codes:
08:12.07.08

# ATC_Codes:
J01DH02

# Absorption:
Not Available

# Biotransformation:
Primarily excreted unchanged. There is one metabolite which is microbiologically inactive.

# Brand_Mixtures:
Not Available

# Brand_Names:
Meronem
Merrem
Merrem I.V.

# CAS_Registry_Number:
119478-56-7

# ChEBI_ID:
43968

# Chemical_Formula:
C17H25N3O5S

# Chemical_IUPAC_Name:
(4R,5S,6S)-3-{[(3S,5S)-5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2218496

# Description:
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.

# Dosage_Forms:
Powder, for solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Antibacterials for Systemic Use

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Sparingly

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Meropenem

# HET_ID:
MER

# Half_Life:
Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.

# InChI_Identifier:
InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1

# InChI_Key:
InChIKey=DMJNNHOOLUXYBV-PQTSNVLCSA-N

# Indication:
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: <b>complicated skin and skin structure infections</b> due to <i>Staphylococcus aureus</i> (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), <i>Streptococcus pyogenes</i>, <i>Streptococcus agalactiae</i>, viridans group streptococci, <i>Enterococcus faecalis</i> (excluding vancomycin-resistant isolates), <i>Pseudomonas aeruginosa</i>, <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Bacteroides fragilis</i> and <i>Peptostreptococcus</i> species; <b>complicated appendicitis and peritonitis</b> caused by viridans group streptococci, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Pseudomonas aeruginosa</i>, <i>Bacteroides fragilis</i>, <i>B. thetaiotaomicron</i>, and <i>Peptostreptococcus</i> species. Also for use in the treatment of bacterial meningitis caused by <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i> (b-lactamase and non-b-lactamase-producing isolates), and <i>Neisseria meningitidis</i>.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02222

# LIMS_Drug_ID:
760

# Mechanism_Of_Action:
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding- protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of <i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i>; and PBPs 1, 2 and 4 of <i>Staphylococcus aureus</i>.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
383.463

# Molecular_Weight_Mono:
383.151491615

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164764445

# Pharmacology:
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.

# Predicted_LogP_Hydrophobicity:
-0.69

# Predicted_LogS:
-1.8

# Predicted_Water_Solubility:
5.63e+00 g/l

# Primary_Accession_No:
DB00760

# Protein_Binding:
Approximately 2%.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic2/meropen.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01097
EXPT02153

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]1([C@@H](C)O)C(=O)N2C(C(O)=O)=C(S[C@@H]3CN[C@@H](C3)C(=O)N(C)C)[C@H](C)[C@]12[H]

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Antibiotic SM 7338
Meropenem anhydrous
Meropenemum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.

# Update_Date:
2013-02-08 16:19:37 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Meropenem

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
bla

# Phase_1_Metabolizing_Enzyme_1_ID:
2340

# Phase_1_Metabolizing_Enzyme_1_Name:
Beta-lactamase PSE-2

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Beta-lactamase PSE-2 precursor
MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARAS
KEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVF
QQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLYLNKLSA
SKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMD
IDNESKLPLRKSIPTKIMESEGIIGG

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P14489

# Drug_Target_1_Cellular_Location:
Periplasm (Potential)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11353613	Ubukata K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, Sunakawa K, Inoue M, Konno M: Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9099227	Kanazawa K, Nouda H, Sunagawa M: Structure-activity relationships of carbapenem compounds to anti-Haemophilus influenzae activity and affinity for penicillin-binding proteins. Effect of 1 beta-methyl group and C-2 side chain. J Antibiot (Tokyo). 1997 Feb;50(2):162-8.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X59460

# Drug_Target_1_GenBank_ID_Protein:
41216

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
dacB

# Drug_Target_1_Gene_Sequence:
>1434 bp
ATGCGATTTTCCAGATTTATCATCGGATTGACCAGCTGTATAGCGTTCAGTGTTCAGGCC
GCAAATGTTGATGAGTACATTACTCAACTCCCCGCTGGTGCCAACCTTGCCCTGATGGTG
CAAAAAGTCGGCGCGTCGGCCCCCGCTATTGATTACCACAGTCAGCAGATGGCGCTGCCT
GCCAGTACCCAGAAAGTGATTACTGCGCTGGCGGCGTTGATTCAACTCGGCCCCGATTTT
CGTTTTACCACGACGCTTGAAACCAAAGGCAATGTGGAAAACGGCGTACTTAAGGGTGAC
TTAGTGGCGCGATTTGGTGCCGATCCGACGTTAAAACGTCAGGATATTCGCAATATGGTC
GCGACTTTGAAAAAATCTGGCGTCAACCAAATCGATGGCAATGTGTTGATAGATACCTCC
ATTTTCGCCAGCCACGATAAAGCCCCCGGCTGGCCATGGAATGACATGACACAATGCTTT
AGCGCTCCGCCTGCCGCCGCCATAGTTGACCGCAACTGTTTCTCCGTCTCGCTCTACAGT
GCCCCAAAGCCTGGTGATATGGCTTTTATACGCGTGGCATCTTATTACCCCGTTACGATG
TTCAGCCAGGTACGCACCCTCCCCCGTGGTTCTGCCGAAGCGCAATACTGCGAACTGGAT
GTGGTGCCAGGCGACCTGAACCGCTTTACGCTGACGGGATGCCTGCCACAACGTTCTGAG
CCGCTCCCGTTGGCTTTTGCCGTGCAGGATGGAGCCAGCTATGCCGGTGCAATTCTGAAA
GATGAGTTAAAACAGGCGGGTATCACCTGGAGCGGAACACTGCTGCGCCAGACTCAGGTT
AACGAACCTGGAACGGTAGTTGCCAGTAAACAGTCGGCCCCGCTGCACGATCTGCTTAAG
ATTATGCTGAAAAAGTCGGACAACATGATCGCCGATACGGTTTTCCGCATGATAGGCCAT
GCGCGCTTCAATGTGCCTGGAACATGGCGGGCCGGGTCGGACGCCGTGCGTCAGATCCTG
CGCCAGCAAGCCGGTGTCGATATTGGAAACACCATTATTGCCGATGGTTCAGGGCTTTCG
CGGCATAACCTGATTGCCCCCGCCACCATGATGCAGGTGCTGCAATACATTGCCCAACAC
GACAATGAACTTAACTTTATCTCCATGCTGCCGCTGGCGGGCTATGACGGCTCTTTGCAG
TACCGTGCAGGTCTGCATCAGGCGGGCGTGGATGGAAAAGTCTCAGCGAAAACCGGTTCG
TTGCAGGGGGTATATAACCTGGCGGGATTCATTACCACAGCGAGCGGGCAACGAATGGCG
TTTGTGCAATATCTTTCTGGCTATGCAGTAGAACCTGCGGATCAGCGTAATCGCCGTATT
CCGTTAGTGCGTTTTGAAAGCCGTTTGTATAAAGATATTTATCAGAACAATTAG

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
2040429	Mottl H, Terpstra P, Keck W: Penicillin-binding protein 4 of Escherichia coli shows a novel type of primary structure among penicillin-interacting proteins. FEMS Microbiol Lett. 1991 Mar 1;62(2-3):213-20.
2046551	Korat B, Mottl H, Keck W: Penicillin-binding protein 4 of Escherichia coli: molecular cloning of the dacB gene, controlled overexpression, and alterations in murein composition. Mol Microbiol. 1991 Mar;5(3):675-84.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
819

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
51799

# Drug_Target_1_Name:
Penicillin-binding protein 4

# Drug_Target_1_Number_of_Residues:
477

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02113	Peptidase_S13

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 4 precursor
MRFSRFIIGLTSCIAFSVQAANVDEYITQLPAGANLALMVQKVGASAPAIDYHSQQMALP
ASTQKVITALAALIQLGPDFRFTTTLETKGNVENGVLKGDLVARFGADPTLKRQDIRNMV
ATLKKSGVNQIDGNVLIDTSIFASHDKAPGWPWNDMTQCFSAPPAAAIVDRNCFSVSLYS
APKPGDMAFIRVASYYPVTMFSQVRTLPRGSAEAQYCELDVVPGDLNRFTLTGCLPQRSE
PLPLAFAVQDGASYAGAILKDELKQAGITWSGTLLRQTQVNEPGTVVASKQSAPLHDLLK
IMLKKSDNMIADTVFRMIGHARFNVPGTWRAGSDAVRQILRQQAGVDIGNTIIADGSGLS
RHNLIAPATMMQVLQYIAQHDNELNFISMLPLAGYDGSLQYRAGLHQAGVDGKVSAKTGS
LQGVYNLAGFITTASGQRMAFVQYLSGYAVEPADQRNRRIPLVRFESRLYKDIYQNN

# Drug_Target_1_Reaction:
Preferential cleavage: (Ac)2-L-Lys-D-Ala!D-Ala. Also transpeptidation of peptidyl-alanyl moieties that are N-acyl substituents of D-alanine INHIBITOR Penicillin; beta-Lactam antibiotics

# Drug_Target_1_Signals:
1-20

# Drug_Target_1_Specific_Function:
Not involved in transpeptidation but exclusively catalyzes a DD-carboxypeptidase and DD-endopeptidase reaction

# Drug_Target_1_SwissProt_ID:
P24228

# Drug_Target_1_SwissProt_Name:
DACB_ECOLI

# Drug_Target_1_Synonyms:
D-alanyl-D-alanine-endopeptidase
DD- carboxypeptidase
DD-peptidase
EC 3.4.16.4
EC 3.4.99.-
PBP-4
Penicillin-binding protein 4 precursor

# Drug_Target_1_Theoretical_pI:
9.02

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00760
